News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Geron Corporation (GERN)'s Telomerase Inhibitor Drug May Benefit Breast Cancer Patients Receiving Radiation Therapy



12/19/2006 12:49:56 PM

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today reported that its telomerase inhibitor drug, GRN163L, may benefit breast cancer patients receiving radiation therapy, according to the results of a study published online in the International Journal of Radiation Oncology, Biology and Physics (www.redjournal.org/inpress).

Read at BioSpace.com
Read at AP
Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES